Elanix Biotechnologies AG is a Germany-based provider of solutions for tissue regeneration. The Company develops and commercializes products for acute wound care, dermatological and gynecological applications, and also provides cell technology services. It develops bioresorbable & bioactive skin dressing derived from progenitor skin fibroblasts. The Company's product portfolio comprises Gyn-RepAir cream, which contains a Cell Free Protein Complex (CFPC), and which includes various proteins such as collagen and fibronectin, as well as RepAir-A N cream. The Company also produces validated progenitor skin cells used in drug discovery, toxicity testing and cosmetic applications. It is a spin-out from the University Hospital of Lausanne (CHUV) in Switzerland.
More about the company